A5001608068- Multiple Sclerosis Research Studies
- Parkinson's Disease Mechanisms and Treatments
- Neuroinflammation and Neurodegeneration Mechanisms
- Nerve injury and regeneration
- SARS-CoV-2 and COVID-19 Research
- Neurogenesis and neuroplasticity mechanisms
- Immunotherapy and Immune Responses
- Peripheral Neuropathies and Disorders
- Acute Lymphoblastic Leukemia research
- Health Systems, Economic Evaluations, Quality of Life
- Autoimmune and Inflammatory Disorders Research
- Alzheimer's disease research and treatments
- Viral Infections and Immunology Research
- Cell Image Analysis Techniques
- Nuclear Receptors and Signaling
- Sphingolipid Metabolism and Signaling
- Cellular Mechanics and Interactions
- Cell Adhesion Molecules Research
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Stress Responses and Cortisol
- Rheumatoid Arthritis Research and Therapies
- Cystic Fibrosis Research Advances
- Polyomavirus and related diseases
- Healthcare Systems and Reforms
- Pneumocystis jirovecii pneumonia detection and treatment
Novartis (Germany)
2017-2024
Novartis (France)
2021-2022
Friedrich-Alexander-Universität Erlangen-Nürnberg
2013-2018
Universitätsklinikum Erlangen
2013-2018
Institute for Research Information and Quality Assurance
2011
Progressive accumulation of α-synuclein (α-syn) in limbic and striatonigral systems is associated with the neurodegenerative processes dementia Lewy bodies (DLB) Parkinson's disease (PD). The murine Thy-1 (mThy1)-α-syn transgenic (tg) model recapitulates aspects degenerative α-syn these disorders. Given that axonal synaptic pathologies are important features DLB PD, we sought to investigate extent characteristics alterations mThy1-α-syn tg mice determine contribution c-terminally cleaved at...
Abstract Neuroinflammation and oligodendroglial cytoplasmic α‐synuclein (α‐syn) inclusions (GCIs) are important neuropathological characteristics of multiple system atrophy (MSA). GCIs known to interfere with maturation consequently result in myelin loss. The neuroinflammatory phenotype the context MSA, however, remains poorly understood. Here, we demonstrate MSA‐associated neuroinflammation being restricted myeloid cells tightly linked α‐syncleinopathy. In human putaminal post‐mortem tissue...
Parkinson's disease, neuropathologically defined by the aggregation of α-synuclein, is characterized neuropsychiatric symptoms such as depression and anxiety preceding onset motor symptoms. A loss serotonergic neurons or their projections into hippocampus alterations in serotonin release may be linked to these Here, we investigate effect human A53T α-synuclein on using 12-months-old transgenic mice. We detected perikarya brainstem median dorsal raphe well fibers hippocampus. Despite...
Nonmotor symptoms of cognitive and affective nature are present in premotor motor stages Parkinson's disease (PD). Neurogenesis, the generation new neurons, persists throughout mammalian life span hippocampal dentate gyrus. Adult neurogenesis may be severely affected course PD, accounting for some neuropsychiatric such as depression impairment. Two important PD‐related pathogenic factors have separately been attributed to contribute both PD adult neurogenesis: dopamine depletion accumulation...
To evaluate the 5-year real-world benefit-risk profile of fingolimod in patients with relapsing-remitting MS (RRMS) Germany.Post-Authorization Non-interventional German sAfety study GilEnyA (PANGAEA) is a non-interventional to prospectively assess effectiveness and safety routine clinical practice Germany. The follow-up period comprised 5 years. Patients were included if they had been diagnosed RRMS prescribed as part routine. There no exclusion criteria except contraindications for defined...
Increased α-synuclein immunoreactivity has been associated with inflammatory activity in multiple sclerosis (MS) lesions, but the function of neuroinflammation remains unknown. The aim this study was to examine role immunological processes murine experimental autoimmune encephalomyelitis (EAE) as a model MS. We studied EAE wildtype (aSyn+/+) and knockout (aSyn−/−) mice on C57BL/6N background. In spleen spinal cord aSyn+/+ mice, we observed gradual reduction expression during EAE, starting...
Background: It is unclear whether multiple sclerosis (MS) patients receiving ofatumumab mount an immune response after SARS-CoV-2 mRNA vaccination. Methods: KYRIOS ongoing, multicenter, open-label, prospective clinical study on responses in MS initial or booster vaccination prior to (cohort 1) during 2) treatment. We report one-week and one-month results of the A comparison with vaccinated while beta-interferon, glatiramer acetate, dimethyl fumarate, teriflunomide no treatment was included...
Survey-based studies are frequently used to describe the economic impact of multiple sclerosis (MS). However, there is no validated health resource survey available, preventing comparison study results and meaningful conclusions regarding efficiency long-term treatments.The aim this was develop validate a tablet- paper-based MS utilization survey.We developed Multiple Sclerosis Health Resource Utilization Survey (MS-HRS), consisting 24 cost items for paper tablet users. Data validation came...
Evidence suggests that early highly efficacious therapy in relapsing multiple sclerosis is superior to escalation strategies.
BackgroundThe risk of progressive multifocal leukoencephalopathy limits the duration over which patients can receive natalizumab before requiring a switch to other therapies such as fingolimod. To date, no studies have assessed long-term real-world effectiveness and safety fingolimod following from natalizumab. We aimed investigate benefit–risk profile 48 months in switching natalizumab, impact washout after discontinuation on outcomes during treatment.MethodsThis analysis used data PANGAEA,...
Relapses are the hallmark of multiple sclerosis (MS). Analyses have shown that cost MS increases during periods relapse. However, results inconsistent between studies, possibly due to different study designs and implications relapses with respect patient characteristics.The aims were estimate describe direct indirect relapse costs determine differences in characteristics. Furthermore, we pharmacoeconomic impact follow-up.Data extracted from two German, multicenter, observational studies...
Background: Few data exist on how ofatumumab treatment impacts SARS-CoV-2 booster vaccination response. Methods: KYRIOS is an ongoing prospective open-label multicenter study the response to initial and mRNA before or during in relapsing MS patients. The results cohort have been published previously. Here, we describe 23 patients who received their outside of but study. Additionally, report two cohort. primary endpoint was SARS-CoV-2-specific T-cell at month 1. Furthermore, serum total...
Background: Fingolimod (Gilenya®) is approved for adult and pediatric patients with highly active relapsing–remitting multiple sclerosis (RRMS). Objectives: The objective was to describe the effectiveness of fingolimod in young adults compared older clinical practice. Methods: PANGAEA largest prospective, multi-center, non-interventional, long-term study evaluating RRMS. We descriptively analyzed demographics, MS characteristics, severity two subgroups (≤20 >20 ≤30 years) (>30...
Booster vaccinations against SARS-CoV-2 are recommended 6–12 months after the last dose or infection in elderly and high-risk groups. The present analysis aims to evaluate whether an interval shorter than 12 is required multiple sclerosis patients receiving ofatumumab. Neutralizing antibody status over 1 year booster vaccination non-interventional, multicenter KYRIOS study under continued ofatumumab treatment was analyzed. Fifteen were included. At time of first vaccination, ten seropositive...